Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

Bladder cancer is a prevalent malignancy with limited therapeutic options, particularly for patients who are unresponsive to Bacillus Calmette-Guérin (BCG). The approval of interferon-α (IFNα) gene therapy with nadofaragene firadenovec (Adstiladrin(®)), the first gene therapy for genitourinary malig...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Alberto, Tholomier, Côme, Mokkapati, Sharada, Dinney, Colin P. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495564/
https://www.ncbi.nlm.nih.gov/pubmed/37705979
http://dx.doi.org/10.3389/fimmu.2023.1260498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495564/
https://www.ncbi.nlm.nih.gov/pubmed/37705979
http://dx.doi.org/10.3389/fimmu.2023.1260498

Ejemplares similares